Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data By Investing.com

Published on 15 Mar 2024 on Investing.com

Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data

Read the rest of the article

Start tracking your investments with Statfolio

As the S&P 500 nears record highs, fueled by a surge in AI stocks and robust earnings reports,...

Simply Wall St. · via Yahoo Finance 23 Jan 2025

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and ...

Simply Wall St. · via Yahoo Finance 22 Nov 2024

On Thursday, Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first...

Benzinga · via Yahoo Finance 22 Sep 2024

Potential Immuneering Corporation (NASDAQ:IMRX) shareholders may wish to note that the Director, ...

Simply Wall St. via Yahoo Finance 21 Mar 2024

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stock...

Investing.com 18 Mar 2024

Immuneering Corporation IMRX is a clinical-stage biotech company focused on developing universal-...

Zacks via Yahoo Finance 18 Mar 2024

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion ...

Benzinga 15 Mar 2024

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points...

Benzinga 15 Mar 2024

Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data

Investing.com 15 Mar 2024

Investing.com 15 Mar 2024